# Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

> **NCT00471965** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 371 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Oxaliplatin + 5-Fluorouracil/Leucovorin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00471965
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2010-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471965, "Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00471965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*